

**DESCRIPTION**

<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human SLAM/CD150 in direct ELISAs and Western blots.
<b>Source</b>	Monoclonal Mouse IgG <sub>1</sub> Clone # 542301
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Mouse myeloma cell line NS0-derived recombinant human SLAM/CD150 Ala21-Pro237 Accession # Q13291
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.

**APPLICATIONS**

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Western Blot</b>	2 µg/mL	See Below
<b>Flow Cytometry</b>	2.5 µg/10 <sup>6</sup> cells	See Below
<b>CyTOF-ready</b>	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.	

**DATA**

<p><b>Western Blot</b></p> <p><b>Detection of Human SLAM/CD150 by Western Blot.</b> Western blot shows lysates of HeLa human cervical epithelial carcinoma cell line and human peripheral blood mononuclear cells (PBMC) untreated (-) or treated (+) with 10 ng/mL PMA and 200 ng/mL ionomycin for 48 hours. PVDF membrane was probed with 2 µg/mL of Mouse Anti-Human SLAM/CD150 Monoclonal Antibody (Catalog # MAB1642), followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for SLAM/CD150 at approximately 85 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.</p>	<p><b>Flow Cytometry</b></p> <p><b>Detection of SLAM/CD150 in Human Lymphocytes by Flow Cytometry.</b> Human peripheral blood lymphocytes were stained with Mouse Anti-Human SLAM/CD150 Monoclonal Antibody (Catalog # MAB1642, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Allophycocyanin-conjugated Anti-Mouse IgG F(ab')<sub>2</sub> Secondary Antibody (Catalog # F0101B).</p>
---	---

**PREPARATION AND STORAGE**

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

Signaling lymphocytic activation molecule (SLAM, SLAMF1; CD150) was the first identified of a family of type I transmembrane (TM) lymphocyte activating receptors. SLAM homotypic adhesion bidirectionally stimulates T and B cells. SLAM is also expressed by hematopoietic stem cells, dendritic cells and platelets and is a T cell measles virus receptor. The 70 kDa glycoprotein contains a 216 amino acid (aa) extracellular domain (ECD) with one C2 type and one V type Ig-like domain, a 20 aa TM sequence and a 76 aa SH2-binding cytoplasmic domain. One splice variant has a shorter cytoplasmic tail and another lacks the TM sequence and is secreted. Human and mouse SLAM ECD share 60% aa identity.